Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.

@article{Cho2014BreastCE,
  title={Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.},
  author={Nariya Cho and Seock Ah Im and In Ae Park and Kyung-Hun Lee and Mulan Li and Wonshik Han and Dong-Young Noh and Woo Kyung Moon},
  journal={Radiology},
  year={2014},
  volume={272 2},
  pages={
          385-96
        }
}
PURPOSE To prospectively compare the performance of dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging using parametric response map (PRM) analysis with that using pharmacokinetic parameters (transfer constant [K(trans)], rate constant [kep ], and relative extravascular extracellular space [ve]) in the early prediction of pathologic responses to neoadjuvant chemotherapy (NAC) in breast cancer patients. MATERIALS AND METHODS The institutional review board approved this… 
Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer.
TLDR
Although changes in Ktrans and IAUC90 are helpful in predicting NACR, they do not show significant association with survival, and early RECIST size change measured by MRI remains the strongest predictor of overall patient survival.
Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer
TLDR
Quantitative analysis of D CE-MRI and DCE-US was helpful for early prediction of response to NAC.
DCE-MRI and parametric imaging in monitoring response to neoadjuvant chemotherapy in breast carcinoma: a preliminary report
Purpose Neoadjuvant chemotherapy is recommended in patients with locally advanced breast cancer. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) enables evaluation of the tumour
Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy
  • N. Cho, S. Im, +8 authors K. J. Suh
  • Medicine
    European Journal of Nuclear Medicine and Molecular Imaging
  • 2017
TLDR
18F-FDG PET/MRI can be used to predict non-pCR after the first cycle of NAC in patients with breast cancer and has the potential to improve sensitivity by the addition of MRI parameters to the PET parameters.
Radiomics of Tumor Heterogeneity in Longitudinal Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer
TLDR
Changes in DCE-MRI features that reflect a reduction in tumor heterogeneity following NACT could provide early prediction of breast tumor response, and was improved when the molecular subtype information was combined into the model.
Quantitative Predictors of Response to Neoadjuvant Chemotherapy on Dynamic Contrast-enhanced 3T Breast MRI
To assess whether changes in quantitative parameters on breast MRI better predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer than change in volume.
Comparison of Model-Free and Model-Based Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacokinetic Parameters for Predicting Breast Cancers' Response to Neoadjuvant Chemotherapy
TLDR
Model-based and model-free DCE parameters, especially Ktrans and TIC, have similar performance in predicting the efficacy of NACT for breast cancers.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
Use of dynamic contrast-enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy.
TLDR
Dynamic contrast-enhanced MR imaging parameters, in conjunction with traditional prognostic factors, have the potential to be prognostic biomarkers for disease-free and overall survival in primary breast cancer.
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.
TLDR
Reductions in MR imaging-determined size of the primary tumor best predict clinicopathologic response of breast cancer after one cycle of neoadjuvant chemotherapy.
Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
TLDR
Patients who show greater reduction in tCho compared with changes in tumor size are more likely to achieve pathologic complete response (pCR), and the change in tumor sizes halfway through therapy was the most accurate predictor of pCR.
Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation.
TLDR
Smaller reduction in tumor volume and a smaller reduction in washout component on DCE MR images assessed with computer-aided evaluation after NAC were independent parameters of worse recurrence-free survival and overall survival in breast cancer patients who received NAC.
Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
TLDR
Changes in breast tumor microvessel functionality as depicted by DCE-MRI early on after starting anthracycline-based neoadjuvant chemotherapy can predict final clinical and pathologic response.
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
TLDR
MR imaging findings are a stronger predictor of pathologic response to NACT than clinical assessment, with the greatest advantage observed with the use of volumetric measurement of tumor response early in treatment.
Quantitative analysis of clinical dynamic contrast-enhanced MR imaging for evaluating treatment response in human breast cancer.
TLDR
The T1-FCM method is more accurate than other methods and is relatively insensitive to the effects of noise and incorrect T1(0) selection, which could prove useful in the evaluation of breast cancer therapy.
Optical Mammography Using Diffuse Optical Spectroscopy for Monitoring Tumor Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer
TLDR
Diffuse optical spectroscopy allows for tumor response assessment and is able to differentiate between responders and nonresponders after the first chemotherapy cycle and halfway treatment and was equally effective in predicting tumor response halfway treatment compared with DCE-MRI.
...
1
2
3
4
...